Mosaic ImmunoEngineering Inc (CPMV)

[ccraider]

....PDS, as an unconsolidated equity investee, recognizes revenue from technology license agreements at the time a contract is entered into, the license method is determined (paid-in-advance or on-going royalty), performance obligations under the license agreement are satisfied, and the realization of revenue is assured which is generally upon the receipt of the license proceeds. PDS may at times enter into license agreements whereby contingent revenues are recognized as one or more contractual milestones are met...

Sec page 23

IMO some time ago, there was discussion if one or another license was "on-going-royalty"...

anyone remembers?

Would this match with this wording (no new license from the PDS view):

...PDS has experienced a decline in licensing revenues and has not obtained significant license revenues since September 2013 and it is unclear when any additional licensing revenues may be generated....